Zacks Investment Research
05 Aug 2026, 18:51 UTC · 55m ago
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
05 Aug 2026, 18:51 UTC · 55m ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
TransMedics Group reported Q2 2026 earnings per share of 44 cents, representing a 52.2% year-over-year decline and a 12% miss against consensus estimates. — A significant double-digit miss in EPS combined with a sharp year-over-year decline typically triggers negative investor sentiment and downward price pressure.
-0.60TransMedics' total operating expenses increased 49.1% year-over-year to $89.5 million, driven by a 98.5% surge in R&D and clinical trials spending. — Rapidly escalating operational costs and R&D spend are weighing on the company's adjusted operating profit, which declined 29.5%.
-0.40TransMedics' Q2 revenues rose 20.7% year-over-year to $189.9 million, exceeding consensus estimates by 3.1%. — Top-line growth and a beat on revenue estimates indicate healthy demand for OCS and logistics services, partially offsetting the earnings miss.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
TransMedics' Transplant Logistics services revenues grew 39% year-over-year to approximately $41 million. — Strong growth in the high-value logistics segment suggests successful scaling of their aviation-fleet and market adoption.
+0.20Which stocks this story touches
Company missed EPS estimates, saw a 52.2% year-over-year drop in EPS, and experienced a significant stock price decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
